Abstracts tagged "SLE"

Abstract Number: 1628 • 2014 ACR/ARHP Annual Meeting
Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Yuka Shimizu, Shinsuke Yasuda, Takashi Kurita, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Toshiyuki Watanabe, Michihito Kono, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Nervous system disease is one of the most common manifestations in patients with systemic lupus erythematosus (SLE) that significantly affects morbidity and mortality. Due…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 238 • 2014 ACR/ARHP Annual Meeting
RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus
Alessandra C. Bonfa¹, Luciana P.C. Seguro², Valéria Caparbo³, Eloisa Bonfa³ and Rosa M R Pereira³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose To evaluate single nucleotide polymorphisms (SNPs) of the receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG) genes in premenopausal systemic lupus erythematosus…
Abstract Number: 2693 • 2014 ACR/ARHP Annual Meeting
Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients
Julia Sieber¹, Capucine Daridon¹, Sarah J. Fleischer¹, Vanessa Fleischer¹, Falk Hiepe¹, Tobias Alexander², Guido Heine³, Gerd Burmester⁴, Simon Fillatreau⁵ and Thomas Dörner¹, ¹Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Charité University Medicine, Dept. Dermatology, Venerology and Allergology, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany, ⁵German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose The role of B cells in immunity has been mainly related to the generation of antibodies and formation of immune complexes. However, B cells…
Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Markos Patsouras¹, Marina Sikara², Athanasios G. Tzioufas² and Panayiotis Vlachoyiannopoulos², ¹PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…
Abstract Number: 1616 • 2014 ACR/ARHP Annual Meeting
Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling
Rachael Hawtin¹, Wouter Korver², Erik Evensen², Diane Longo², Drew Hotson², Nikil Wale², Andy Conroy², Alessandra Cesano², Barbara Mittleman², Shirley Tu², Matt Westfall², Tsung Lin³, Vik Rao⁴, Elena Peeva⁵, Stephen Benoit⁵, Martin Hodge³, James D. Clark³, Jean-Baptiste Telliez³ and Aaron R. Winkler⁴, ¹Nodality Inc., South San Francisco, CA, ²Nodality, Inc., South San Francisco, CA, ³Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁴Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁵Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-system rheumatic disease with widely differing clinical manifestations and outcomes. Treatment is generally immunosuppressive, with no available…
Abstract Number: 710 • 2014 ACR/ARHP Annual Meeting
Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis
Luis J. Jara¹, Nahim Barron², Jesús Arenas-Osuna³, Arturo Vélazquez-García⁴, Arturo González-Zúñiga⁴, Miguel A Saavedra⁵ and Pilar Cruz-Domínguez⁶, ¹Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ²General Surgery, Hospital de Especialidades Centro Médico La Raza, México, Mexico, ³Division of Education, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁴General Surgery, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁵Reumathology, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁶Division of Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose Acute presentation of severe autoinmune thrombocytopenia, and hemolytic anemia in systemic lupus erythematosus (SLE) is associated with high mortality. Splenectomy is the second line…
Abstract Number: 146 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Joint and Tendon Involvement in Patients with Early Systemic Lupus Erythematosus (SLE) in Comparison with Early Rheumatoid Arthritis (RA)
Takehisa Ogura¹, Ayako Hirata¹, Norihide Hayashi¹, Rie Kujime², Hideki Ito², Sayaka Takenaka², Sumie Nakahashi², Kennosuke Mizushina², Naoko Yamashita², Yuki Fujisawa² and Hideto Kameda³, ¹Department of Rheumatology, Toho Univ, Tokyo, Japan, ²Toho Univ, Tokyo, Japan, ³Div Rheumatol, Dep Intern Med, Toho Univ, Tokyo, Japan
Background/Purpose: Although both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) may lead to the joint deformity, different characteristics such as the absence or the…
Abstract Number: 2681 • 2014 ACR/ARHP Annual Meeting
Activated SLE-T Cells Enhance the Interferon-Alpha Production By Plasmacytoid Dendritic Cells Stimulated By RNA-IC
Dag Leonard¹, Maija-Leena Eloranta¹, Niklas Hagberg¹, Olof Berggren¹, Karolina Tandre¹, Gunnar Alm² and Lars Rönnblom¹, ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose A prominent interferon-α (IFNα) signature is seen in several autoimmune diseases including systemic lupus erythematosus (SLE). Plasmacytoid dendritic cells (pDCs) are the main IFNα…
Abstract Number: 1976 • 2014 ACR/ARHP Annual Meeting
Elevation and Functional Activity of Interferon Omega in Human Systemic Lupus Erythematosus
Jarrat Jordan¹, Jessica Schreiter¹, Hao Liu², Sreedevi Adhikarakunnathu², Chichi Huang³ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Immunology Research, Janssen Research and Development, LLC., Spring House, PA, ³Biologics Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose IFNα is emerging as a clinically validated target in SLE yet it is currently unclear if other type I IFNs are contributing to the…
Abstract Number: 1614 • 2014 ACR/ARHP Annual Meeting
Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity
Rachael Hawtin¹, Wouter Korver², Erik Evensen², Diane Longo², Drew Hotson², Nikil Wale², Andy Conroy², Alessandra Cesano², Barbara Mittleman², Tsung Lin³, Vikram R. Rao⁴, Elena Peeva⁵, Stephen Benoit⁵, Martin Hodge³, James D. Clark³, Aaron R. Winkler⁶ and Jean-Baptiste Telliez³, ¹Nodality Inc., South San Francisco, CA, ²Nodality, Inc., South San Francisco, CA, ³Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁴Inflammation & Remodeling, Pfizer, Cambridge, MA, ⁵Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA, ⁶Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA
Background/Purpose: Interferons (IFN) reportedly are central to SLE pathogenesis and increased expression of IFN regulated genes (the ‘IFN signature') is associated with active disease. Clinical…
Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting
Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Lilian Reis¹, Marco Tulio de Mello² and Virginia M. Trevisani³, ¹Internal medicine and therapy, Federal University of Sao Paulo - UNIFESP, SAO PAULO, Brazil, ²Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ³Federal University of São Paulo, São Paulo Brazil, Brazil
Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…
Abstract Number: L8 • 2014 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis
Renuka Nayak¹, Sharon A. Chung², Joanne Nitiham³ and Lindsey A. Criswell³, ¹Rheumatology, University of California - San Francisco, San Francisco, CA, ²School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We now have technologies that allow us to identify these factors…
Abstract Number: 2677 • 2014 ACR/ARHP Annual Meeting
Decreased Levels of SRSF1 (Serin/Arginine-Rich Splicing Factor1) Induced Lower Levels of RasGRP1 in T Cells from Patients with Systemic Lupus Erythematosus
Takashi Kurita¹, Shinsuke Yasuda¹, Vaishali Moulton², Yuka Shimizu¹, Michihito Kono¹, Hideyuki Koide¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, George C. Tsokos³ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Down-regulation of MAP kinase pathway has been recognized in T cells from patients with SLE that results in hypo-methylation of DNA. RasGRP1 is an…
Abstract Number: 1955 • 2014 ACR/ARHP Annual Meeting
Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE
Venkat Reddy¹, Geraldine Cambridge², David A. Isenberg³, Mark Cragg⁴ and Maria J. Leandro², ¹Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose Monoclonal antibodies (mAbs) targeting B cell antigens CD20 and CD22 are used to treat patients with SLE either in the clinic or in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].